| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Outline of Final Research Achievements |
The results of the present study show that the combination of radiofrequency ablation (RFA) and cisplatin (CDDP)/paclitaxel (PTX) treatment had a significant survival benefit compared to control (without treatment), CDDP/PTX alone or RFA treatment alone in a rabbit lung cancer model with a VX2 tumor. In contrast, treatment with a combination of RFA and CDDP/vinorelbine (VNR) or CDDP/pemetrexed (MTA) chemotherapy did not show any survival benefit compared to the control or the platinum doublet alone chemotherapy and resulted in significantly shorter survival compared to RFA treatment alone.
The combination of RFA and systemic platinum-doublet chemotherapy with cisplatin/paclitaxel may improve the local control rate and prolong survival.
|
